InhaleRx Limited (ASX: IRX) Reports Quarterly Activities and Updates
InhaleRx Limited (ASX: IRX) reports on key operational highlights and drug development activities, marking significant progress in clinical trials.

InhaleRx Limited (ASX: IRX) reports on key operational highlights and drug development activities, marking significant progress in clinical trials.
InhalerX Limited (ASX:IRX) reports a quarterly cash flow update, demonstrating the financial trajectory and strategic financing efforts as of December 31, 2024.
Nyrada Inc. (ASX:NYR) outlines advancements in NYR-BI03 and financial strengths in its Quarterly Activities Report.
Universal Biosensors, Inc. (ASX:UBI) has partnered with Chewy and Amazon to enhance sales of its Petrackr product.
Rhythm Biosciences Ltd (ASX:RHY) announces significant quarterly achievements including funding, strategic acquisitions, and product developments.
EZZ Life Science Holdings reported strong Q2 FY25 results, showcasing significant revenue growth and a strategic outlook for future market expansion.
Imricor (ASX: IMR) reports significant regulatory progress and strong revenue growth, setting a positive outlook for Q4 CY24.
Core Lithium Ltd (ASX: CXO) reports on its December quarterly activities, highlighting significant cash reserves, exploration success, and director appointment.
Praemium Limited (ASX:PPS) reports a 29% increase in FUA to $62.1 billion, highlighting strong growth metrics and inflows for Q2 FY2025.
Firebrick Pharma Ltd reports significant operational and financial updates, marking progress in Singapore sales of Nasodine during the December quarter.